In the combined training and validation set comprising of 98 patients with serum AFP data available, the HCC EV TR Score outperformed serum AFP in distinguishing post-Tx viable from post-Tx nonviable HCC, with an AUROC of 0.91 (95% CI: 0.84 – 0.97; Fig. 7E). This evidence concerns the gene AFP and hepatocellular carcinoma.